

-continued

---

Phe	Pro	Tyr	Leu	Asp	Pro	Phe	Asp	Ser	Ala	Ser	Gln	Leu	Met	Glu	Pro
	355						360					365			
Gly	Arg	Gln	Ser	Met	Asp	Leu	Val	Glu	Leu	Val	Ser	Leu	Phe	Pro	Thr
	370					375					380				
Leu	Ala	Gly	Leu	Ala	Gly	Leu	Gln	Val	Pro	Pro	Arg	Cys	Pro	Val	Pro
385					390					395				400	
Ser	Phe	His	Val	Glu	Leu	Cys	Arg	Glu	Gly	Lys	Asn	Leu	Leu	Lys	His
			405						410					415	
Phe	Arg	Phe	Arg	Asp	Leu	Glu	Glu	Asp	Pro	Tyr	Leu	Pro	Gly	Asn	Pro
			420					425					430		
Arg	Glu	Leu	Ile	Ala	Tyr	Ser	Gln	Tyr	Pro	Arg	Pro	Ser	Asp	Ile	Pro
	435						440					445			
Gln	Trp	Asn	Ser	Asp	Lys	Pro	Ser	Leu	Lys	Asp	Ile	Lys	Ile	Met	Gly
	450					455					460				
Tyr	Ser	Ile	Arg	Thr	Ile	Asp	Tyr	Arg	Tyr	Thr	Val	Trp	Val	Gly	Phe
465					470					475					480
Asn	Pro	Asp	Glu	Phe	Leu	Ala	Asn	Phe	Ser	Asp	Ile	His	Ala	Gly	Glu
				485				490						495	
Leu	Tyr	Phe	Val	Asp	Ser	Asp	Pro	Leu	Gln	Asp	His	Asn	Met	Tyr	Asn
			500					505					510		
Asp	Ser	Gln	Gly	Gly	Asp	Leu	Phe	Gln	Leu	Leu	Met	Pro			
	515						520				525				

---

1. An antibody or an antigen-binding fragment that binds to serum albumin comprising three complementarity determining regions (CDR1, CDR2 and CDR3), wherein said CDR1, CDR2 and CDR3 comprise an amino acid sequence comprising:

- 1)  
 GFLLRNTM, (SEQ ID NO: 1)  
 IRPSGLT, (SEQ ID NO: 2)  
 and  
 HTRPPFQRDS (SEQ ID NO: 3)  
 or  
 ATRPPFQRDS, (SEQ ID NO: 4)  
 respectively; or  
 2)  
 GRTFIAYAM, (SEQ ID NO: 5)  
 ITNFAGGTT, (SEQ ID NO: 6)  
 and  
 AADRSAQTMRQVRPVLPHY, (SEQ ID NO: 7)  
 respectively; or

-continued

- 3)  
 GRTFDNYVM, (SEQ ID NO: 8)  
 ISGSGSIT, (SEQ ID NO: 9)  
 and  
 AAGSRRTYYREPKFYPS, (SEQ ID NO: 10)  
 respectively; or  
 4)  
 GSTFSSSSV, (SEQ ID NO: 11)  
 ITSGGST, (SEQ ID NO: 12)  
 and  
 NVAGRNVWPISRYSPGPY (SEQ ID NO: 13)  
 or  
 AVAGRNVWPISRYSPGPY, (SEQ ID NO: 14)  
 respectively; or  
 5)  
 GSIESINRM, (SEQ ID NO: 15)  
 ISKGGST, (SEQ ID NO: 16)  
 and  
 AAGPVWEQF, (SEQ ID NO: 17)  
 respectively; or